Mizuho Maintains Buy on Adverum Biotechnologies, Raises Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Adverum Biotechnologies (ADVM) and raises the price target from $2 to $4.
February 06, 2024 | 7:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Adverum Biotechnologies and raises the price target from $2 to $4.
The upgrade in price target by a reputable analyst like Graig Suvannavejh is likely to instill confidence among investors, potentially driving up the stock price in the short term. The doubling of the price target reflects a strong bullish outlook on the company's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100